淫羊藿-巴戟天治疗新型冠状病毒感染肺肾两虚型的网络药理学分析  

Network pharmacological analysis of Epimedium and Morinda officinalis for COVID-2019 with deficiency of lung and kidney

作　　者：张立 周继红 谢嘉嘉 焦小强 李珏卉 何逸龙 ZHANG Li;ZHOU Jihong;XIE Jiajia;JIAO Xiaoqiang;LI Juehui;HE Yilong(Department of Pulmonary Disease,Shenzhen Bao′an Traditional Chinese Medicine Hospital Group,Shenzhen,Guangdong 518100,China)

机构地区：[1]深圳市宝安中医院(集团)肺病科,广东深圳518100

出　　处：《现代医药卫生》2023年第3期404-410,414,共8页Journal of Modern Medicine & Health

摘　　要：目的 运用网络药理学方法探讨淫羊藿-巴戟天治疗新型冠状病毒感染(新冠感染)肺肾两虚型的潜在作用机制。方法 通过中药系统药理学数据库与分析平台检索淫羊藿、巴戟天含有的化合物,筛选其活性成分及其作用靶点;运用Uniprot数据库进行标准化处理,查询靶点对应的基因;通过GeneCards数据库获取新冠感染肺肾两虚型的相关靶标;采用Cytoscape 3.7.2软件构建药物-化合物-靶点网络,STRING数据库进行蛋白质相互作用(PPI)网络的构建与分析;通过Funrich3.1.3软件进行基因本体(GO)富集分析和京都基因与基因组百科全书(KEGG)通路分析。结果 获得淫羊藿-巴戟天治疗新冠感染的共41个有效靶点,新冠感染肺肾两虚型相关靶点2 831个,关键靶点有白细胞介素-6(IL-6)、血管内皮生长因子A(VEGFA)、胱天蛋白酶3(CASP3)、缺氧诱导因子1α(HIF1α)、细胞周期蛋白D1(CCND1)、人类表皮生长因子受体(EGFR)等;获得802个GO富集条目和125条KEGG通路,主要涉及磷酸肌醇-3激酶/蛋白激酶B信号通路、脂质核动脉粥样硬化、卡波西氏肉瘤疱疹病毒感染、肿瘤相关mRNA、人巨细胞病毒感染、艾巴氏病毒感染等。结论 淫羊藿-巴戟天治疗新冠感染肺肾两虚型是多靶点、多途径相互作用的结果,可作为新冠感染肺肾两虚型的辅助治疗方法,为扩展喘可治注射液的临床应用提供一定理论依据。Objective To explore the potential mechanism of Epimedium and Morinda officinalis in the treatment of Corona Virus Disease 2019(COVID-19) with deficiency of lung and kidney by network pharmacology.Methods The Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform was used to search the compounds in Epimedium and Morinda, and the active components and targets were screened.Uniprot database was used for standardization, and the genes corresponding to the targets were searched.GeneCards database was used to obtain the targets of COVID-19 with deficiency of lung and kidney.The drug-compound-target network was constructed by the software of Cycloscape3.7.2,protein-protein interaction(PPI) network was constructed and analyzed by using Search Tool for the Retrieval of Interacting Genes(STRING) database.Gene Ontology(GO) enrichment analysis and Kyoto Encyclopedia of Genes and Genomes(KEGG) path analysis were conducted by the software of Funrich 3.1.3.Results Epimedium and Morinda officinalis had 41 effective targets in the treatment of COVID-19.There were 2 831 targets associated with COVID-19 with deficiency of lung and kidney, and the key targets were IL6,VEGFA,CASP3,HIF1A,CCND1,EGFR etc.A total of 802 GO enrich-ment entries and 125 KEGG pathways were obtained, mainly involving PI3K-Akt signaling pathway, lipid and atherosclerosis, Kaposi sarcoma-associated herpesvirus infection, microRNAs in cancer, human cytomegalovirus infection, Epstein-Barr virus infection, etc.Conclusion The treatment of COVID-19 with deficiency of lung and kidney is the result of multi-target and multi-channel interaction, and it can be used as an adjuvant therapy for COVID-19 with deficiency of lung and kidney, which provides certain theoretical basis for expanding the clinical application of Chuankezhi injection.

关 键 词：新型冠状病毒感染 肺肾两虚型 淫羊藿 巴戟天 网络药理学 喘可治注射液 

分 类 号：R285.6[医药卫生—中药学]